SCHEMBL3491909

SCHEMBL3491909

O=C(O)N1CCN(Cc2ccccc2)C[C@H]1C=Cc1ccccn1

nearest known ligand 0.47

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 2/20 0.47
CYP2C9 P11712 2/20 0.47
CYP2D6 P10635 1/20 0.46
AGTR2 P50052 1/20 0.46
SIGMAR1 Q99720 1/20 0.42
ALDH1A1 P00352 3/20 0.41
SMN1; SMN2 Q16637 2/20 0.41
DRD2 P14416 1/20 0.41
DRD4 P21917 1/20 0.41
DRD3 P35462 1/20 0.41
NPY2R P49146 1/20 0.41
HTR7 P34969 2/20 0.40
CYP1A2 P05177 1/20 0.40
KDM4E B2RXH2 1/20 0.40
OPRM1 P35372 1/20 0.39
CHRM2 P08172 1/20 0.39
CHRM4 P08173 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3491903 1.00 CYP3A4 (0.47) CYP3A4CYP2C9CYP2D6AGTR2SIGMAR1
SCHEMBL13340716 0.86 CYP3A4 (0.41) CYP3A4CYP2C9CYP2D6AGTR2NPY2R
SCHEMBL3493181 0.80 AGTR2 (0.55) AGTR2SIGMAR1ALDH1A1SMN1; SMN2KDM4E
SCHEMBL3493515 0.80 AGTR2 (0.50) CYP3A4CYP2D6AGTR2SIGMAR1ALDH1A1
SCHEMBL3493519 0.80 AGTR2 (0.50) CYP3A4CYP2D6AGTR2SIGMAR1ALDH1A1
SCHEMBL4281677 0.80 L3MBTL1 (0.47) AGTR2SIGMAR1ALDH1A1SMN1; SMN2KDM4E
SCHEMBL4281674 0.80 L3MBTL1 (0.47) AGTR2SIGMAR1ALDH1A1SMN1; SMN2KDM4E
SCHEMBL8235679 0.73 LTA4H (0.45) CYP3A4CYP2C9CYP2D6SIGMAR1ALDH1A1
Hydrochloric Acid SCHEMBL3493627 0.72 LTA4H (0.44) CYP3A4CYP2C9CYP2D6SIGMAR1ALDH1A1
Hydrochloric Acid SCHEMBL3493621 0.72 LTA4H (0.44) CYP3A4CYP2C9CYP2D6SIGMAR1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100121048-A1 Cyclic Amine Compound and Use Thereof for the Prophylaxis or Treatment of Hypertension TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-05-13 US disclosed
US-20090227560-A1 Substituted imidazole compound and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-09-10 US disclosed
US-20090156612-A1 Substituted imidazole compound and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-06-18 US disclosed
WO-2008139941-A1 SUBSTITUTED IMIDAZOLE COMPOUND AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-11-20 WO disclosed
EP-1984355-A2 CYCLIC AMINE COMPOUND AND USE THEREOF FOR THE PROPHYLAXIS OR TREATMENT OF HYPERTENSION Takeda Pharmaceutical Company Limited (JP) 2008-10-29 EP disclosed
WO-2007094513-A2 CYCLIC AMINE COMPOUND AND USE THEREOF FOR THE PROPHYLAXIS OR TREATMENT OF HYPERTENSION TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2007-08-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100121048-A1 Cyclic Amine Compound and Use Thereof for the Prophylaxis or Treatment of Hypertension REN, AGTR1, AGTR2 CYP3A4 1555/4885CYP2C9 305/4885CYP2D6 783/4885
US-20090156612-A1 Substituted imidazole compound and use thereof REN, ACE, AGT CYP3A4 50/4885CYP2C9 40/4885CYP2D6 173/4885
US-20090227560-A1 Substituted imidazole compound and use thereof REN, ACE, AGT CYP3A4 50/4885CYP2C9 40/4885CYP2D6 173/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.